Combined therapy of empagliflozin and linagliptin is superior to metformin and insulin glargine in improving blood pressure and vascular function in type 2 diabetes

Jung S, Bosch A, Kannenkeril D, Karg M, Striepe K, Bramlage P, Ott C, Schmieder R (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

European Heart Journal Oxford University Press

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Pages Range: 741-741

Conference Proceedings Title: EUROPEAN HEART JOURNAL

Event location: Paris FR

DOI: 10.1093/eurheartj/ehz748.0063

Authors with CRIS profile

Agnes Bosch Department of Medicine 4 – Nephrology and Hypertension Kristina Striepe Professur für Innere Medizin (Nephrologie) Christian Ott Department of Medicine 4 – Nephrology and Hypertension Roland Schmieder Professur für Innere Medizin (Nephrologie)

Involved external institutions

Institut für Pharmakologie und präventive Medizin (IPPMed GmbH) DE Germany (DE)

How to cite

APA:

Jung, S., Bosch, A., Kannenkeril, D., Karg, M., Striepe, K., Bramlage, P.,... Schmieder, R. (2019). Combined therapy of empagliflozin and linagliptin is superior to metformin and insulin glargine in improving blood pressure and vascular function in type 2 diabetes. In EUROPEAN HEART JOURNAL (pp. 741-741). Paris, FR: OXFORD: OXFORD UNIV PRESS.

MLA:

Jung, Susanne, et al. "Combined therapy of empagliflozin and linagliptin is superior to metformin and insulin glargine in improving blood pressure and vascular function in type 2 diabetes." Proceedings of the ESC Congress / World Congress of Cardiology, Paris OXFORD: OXFORD UNIV PRESS, 2019. 741-741.

BibTeX: Download